AbbVie Inc (ABBV)
AbbVie Inc (ABBV) carries a ŷRobot AI score of 71 out of 100. The model's fair value estimate is $306.30, 12.4% above the last close of $272.42. The chart signal reads Sell.
| Metric | ABBV |
|---|---|
| AI score | 71 / 100 |
| Chart signal | Sell |
| Fair value estimate | $306.30 |
| Upside to fair value | 12.4% |
| Previous close | $272.42 |
| P/E | 74.53 |
| Price / sales | 7.14 |
| Market cap | $471.27B |
| EPS | 3.51 |
| Revenue growth | 2.0% |
| 1-year price change | 15.2% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, Merck & Company Inc, UnitedHealth Group Incorporated, Novartis AG ADR, AstraZeneca PLC.
Questions about ABBV
Is ABBV overvalued or undervalued right now?
As of Oct 8, 2026, ŷRobot's fair-value model estimates AbbVie Inc (ABBV) at $306.30 against a last close of $272.42, implying 12.4% upside to the model's estimate.
Is ABBV's chart signal bullish or bearish?
The chart-signal model classifies ABBV as Neutral as of Oct 8, 2026, with a signal score of -0.12 on a -1 to 1 scale.
What is ABBV's ŷRobot AI score?
ABBV scores 71 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Oct 8, 2026.
Is ABBV stock expensive on P/E and P/S?
ABBV trades at 74.5 times earnings and 7.1 times sales as of Oct 8, 2026.
What does ABBV's seasonal forecast show?
ŷRobot's seasonal forecast curve for ABBV reads +0.2% at 30 days, +7.2% at 90 days, and +15.2% at one year as of Oct 8, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is ABBV growing?
AbbVie Inc's revenue growth is +2.0% and free-cash-flow growth is +19.5% on the latest reported figures.
ABBV chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.